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The Parkinson’s disease-associated 
GPR37 receptor interacts with 
striatal adenosine A2A receptor 
controlling its cell surface 
expression and function in vivo
Xavier Morató1,2, Rafael Luján3, Marc López-Cano1,2, Jorge Gandía1,2, Igor Stagljar4, Masahiko 
Watanabe5, Rodrigo A. Cunha6, Víctor Fernández-Dueñas1,2 & Francisco Ciruela1,2
G protein-coupled receptor 37 (GPR37) is an orphan receptor associated to Parkinson’s disease (PD) 
neuropathology. Here, we identified GPR37 as an inhibitor of adenosine A2A receptor (A2AR) cell surface 
expression and function in vivo. In addition, we showed that GPR37 and A2AR do oligomerize in the 
striatum. Thus, a close proximity of GPR37 and A2AR at the postsynaptic level of striatal synapses was 
observed by double-labelling post-embedding immunogold detection. Indeed, the direct receptor-
receptor interaction was further substantiated by proximity ligation in situ assay. Interestingly, 
GPR37 deletion promoted striatal A2AR cell surface expression that correlated well with an increased 
A2AR agonist-mediated cAMP accumulation, both in primary striatal neurons and nerve terminals. 
Furthermore, GPR37−/− mice showed enhanced A2AR agonist-induced catalepsy and an increased 
response to A2AR antagonist-mediated locomotor activity. Overall, these results revealed a key role for 
GPR37 controlling A2AR biology in the striatum, which may be relevant for PD management.
GPR37, also known as parkin-associated endothelin-like receptor (Pael-R), is an orphan G protein-coupled 
receptor (GPCR) expressed in brain regions such as cerebellum, corpus callosum, caudate nucleus, putamen, sub-
stantia nigra and hippocampus1, 2. The physiological function of this receptor has not been still elucidated. Thus, 
GPR37 is known to be expressed in neural progenitor cells and control Wnt signaling3. Also, a GPR37-mediated 
control of oligodendrocyte differentiation has been recently described4, but scarce information exists regarding its 
presence in other neuronal subsets. On the other hand, the neuropathological role of GPR37 has been extensively 
studied. Hence, it is well-established that GPR37 is a substrate for parkin, an E3 ubiquitin ligase involved in the 
ubiquitination and proteasome-mediated degradation/clearance of misfolded proteins5. Indeed, both the loss of 
function of parkin and its toxic accumulation have been found in some states of Parkinson’s disease (PD)6–8. Of 
note, it was recently described that GPR37 suffers constitutive metalloproteinase-mediated proteolysis, which 
results on the release of an N-terminal ectodomain9. Accordingly, this ecto-domain could be responsible for its 
toxicity upon overexpression. Alternatively, a role for GPR37 on neuroprotection has been also suggested, since 
it has been associated with the action of some peptides10. Nevertheless, the toxic effects of GPR37 accumulation 
seem clear in PD. Thus, GPR37 up-regulation, or the presence of GPR37 in Lewy bodies, has been found in brains 
from PD patients11–13. Furthermore, it was shown that the absence of GPR37 in a mouse model of PD (i.e. MPTP) 
protected against dopaminergic cell death14.
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The role of GPR37 in PD has been investigated focusing on the interaction of this orphan receptor with dif-
ferent neurotransmitter systems. In such way, it has been shown that GPR37 deletion increases pre-synaptic 
dopamine transporter (DAT) cell surface expression in the striatum15. Similarly, it has been described that the 
adenosinergic-dependent control of anxiety behavior is modified in GPR37 deficient mice (GPR37−/−)2, and 
that upon deletion of GPR37, adenosine A2A receptors (A2AR) antagonists cannot revert pilocarpine-induced 
tremor, which is a model for parkinsonism16. On the other hand, some data point to the existence of direct 
receptor-receptor interactions involving GPR37. Thus, it was firstly proposed that GPR37 may interact with 
dopamine D2 receptors (D2R)17. Indeed, it has been recently hypothesized that GPR37 and A2AR might form 
receptor-receptor complexes or heteromers in the striatum18, a fact that has not been still wholly demon-
strated. Interestingly, the existence of a direct receptor-receptor interaction between A2AR and dopamine D2 
receptor (D2R) in the striatum was recently demonstrated and proposed as a pharmacological target for PD 
management19. Hence, it could be postulated that the relevance of GPR37 in PD could be related to its interac-
tion with striatal A2AR and/or D2R. Supporting this idea, we recently reported that GPR37−/− mice showed 
lower haloperidol-induced catalepsy18, thus suggesting an altered functioning of postsynaptic striatal D2R20 in 
GPR37−/− mice. In addition, the well-known effects of A2AR antagonists blocking haloperidol-induced cata-
lepsy were higher in the absence of GPR37, thus suggesting a GPR37-dependent A2AR modulation of dopamin-
ergic transmission. Overall, GPR37 may play a key role in the A2AR-D2R interplay and consequently it could be 
considered as a novel target for PD management.
Here, we aimed to validate the existence of GPR37-A2AR oligomers in the striatum and to assess the functional 
impact of this receptor-receptor interaction in vivo. Accordingly, we examined the effects of GPR37 presence/
absence on A2AR localization (cell surface targeting) and function (cAMP accumulation and behavioral activities, 
namely catalepsy and locomotor activity).
Results
Striatal GPR37 and A2AR are enriched at the postsynaptic compartment. By using a systematic 
interactome mapping of protein-protein interactions for the A2AR, we recently identified and validated GPR37 
receptor as a putative interacting partner of A2AR18. Here, we first aimed to wholly demonstrate and characterize 
the existence of this direct receptor-receptor interaction (i.e. GPR37-A2AR oligomerization) in native tissue. To 
this end, we first determined the regional and overlapping localization of these two receptors in the mouse brain 
by using conventional immunohistoblotting. GPR37 was widely distributed throughout the brain with a high 
degree of expression in myelinated tracts including corpus callosum and cerebellar white matter tracts (Fig. 1A), as 
previously described by means of in situ hybridization4. In addition, a moderate to weak labeling was consistently 
detected in cortex, striatum and hippocampus (Fig. 1A and B). Interestingly, no immunostaining was observed 
when brain sections from GPR37−/− were used (Fig. 1A), thus demonstrating the specificity of the antibody 
used (i.e. rabbit anti-GPR37-N). Finally, under the same experimental conditions we found that A2AR expression 
was mostly concentrated in the striatum (Fig. 1), as expected21, 22. Overall, these first experiments pinpointed the 
striatum as a brain region to assess GPR37-A2AR interaction.
Next, we aimed to ascertain the subsynaptic striatal locus where a putative interaction between these two 
receptors might occur. We first evaluated the subcellular localization of GPR37 within the striatum by means 
of immunogold electron microscopy. GPR37 immunoparticles were mostly found at the extrasynaptic plasma 
membrane of dendritic spines of striatal neurons (Fig. 2A, arrows), with few immunoparticles present at intracel-
lular sites (Fig. 2A, crossed arrows). Similarly, in axon terminals establishing asymmetrical synapses with striatal 
spines GPR37 immunoparticles were also localized at the extrasynaptic plasma membrane (Fig. 2A, lower panel, 
arrowheads). Finally, in dendritic shafts, immunoparticles for GPR37 were mainly found at the plasma mem-
brane (Fig. 2A, lower panel arrows). Interestingly, quantitative analysis showed that 26 ± 0.9% of immunopar-
ticles were located presynaptically while 73 ± 0.9% showed a postsynaptic distribution (Fig. 2B), thus matching 
with A2AR distribution within the striatum21. Subsequently, we performed a subsynaptic fractionation of striatal 
nerve terminals, which allowed identifying the localization of GPR37 and A2AR23, 24 in pre-, post- and extrasynap-
tic enriched fractions (Fig. 2C). Interestingly, immunoblot analysis of the different striatal subsynaptic fractions 
revealed a significant (P < 0.05) enrichment at the postsynaptic over the presynaptic fraction of both GPR37 and 
A2AR (Fig. 2C and D), thus showing their superimposable subsynaptic distribution within the striatum. On the 
other hand, we ascertained the well-characterized high A2AR extrasynaptic expression, which has been reported 
to be mostly related to the actions of adenosine acting as an energy-dependent neuromodulator in the SNC, also 
finely sensoring neuronal activity25.
Co-clustering of GPR37 and A2AR in striatum. While biochemical approaches are useful to establish 
the subsynaptic distribution of neuronal proteins they do not provide spatial information. Thus, we aimed to 
determine the proximity between GPR37 and A2AR within striatal neurons by means of double-labelling immu-
nogold electron microscopy and proximity ligation in situ assay (P-LISA). First, it was observed that GPR37 and 
A2AR closely co-distributed along the extrasynaptic plasma membrane of dendritic shafts and dendritic spines 
establishing excitatory synaptic contact with axon terminals (Fig. 3A–D). This result agrees with the previously 
findings reported in the subsynaptic fractionation experiments. Importantly, in the striatum of GPR37−/− mice, 
no GPR37 detection was observed (Fig. 3E), again demonstrating the specificity of the anti-GPR37-N antibody 
used. Overall, these results revealed a close and selective anatomical proximity of GPR37 and A2AR within striatal 
spines.
We next aimed to validate the existence of GPR37/A2AR heteromers in the striatum by means of P-LISA, a 
well described technique that provides enough sensitivity to evaluate receptor’s close proximity within a named 
GPCR oligomer in native conditions26. We first ascertained the immunohistochemistry detection of GPR37 and 
A2AR in the striatum. As expected, both receptors showed a high degree of co-distribution throughout the striatal 
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neuropil (Fig. 4A). Interestingly, no immunostaining was observed when brain slices from GPR37−/− were used 
(Fig. 1A, upper right panel), thus demonstrating the specificity of the antibody used (i.e. rabbit anti-GPR37-C). 
Noteworthy, here we used an antibody directed against the C-terminus of GPR37. This is a mandatory require-
ment for the PLA assay, in which both antibodies must recognize the extracellular or intracellular epitopes of 
the selected putative interacting proteins. Subsequently, we implemented the P-LISA approach, using an ade-
quate combination of antibodies to test the presence of GPR37/A2AR heteromers in the mouse striatum. Notably, 
red dots reflecting a positive P-LISA signal were observed in the striatum of GPR37+/+ mice (Fig. 4B, upper 
panel), thus allowing the visualization of the GPR37/A2AR receptor-receptor interaction. Importantly, in striatal 
slices from GPR37−/− mice the P-LISA signal was negligible (Fig. 4B, lower panel), thus reinforcing the spec-
ificity of our P-LISA assay. Indeed, when the P-LISA signal was quantified, 6.5 ± 1.6 dots/nuclei were observed 
in GPR37+/+ mice, while GPR37−/− mice only displayed 0.9 ± 0.3 dots/nuclei under the same experimental 
conditions. Thus, a marked and significant (P < 0.05) reduction in the P-LISA signal was observed in GPR37−/− 
striatal slices, which strongly supported the existence of GPR37/A2AR heteromers in the mouse striatum.
GPR37 deletion promotes striatal A2AR cell surface expression and function. It has been shown 
that GPR37 cell surface expression in cultured cells can be regulated by co-expressing particular GPCRs, includ-
ing the A2AR17. Indeed, we recently demonstrated that GPR37 and A2AR form heteromers in vitro with an inter-
twined cell surface expression when co-expressed18. However, the function of the GPR37-A2AR interaction in 
native tissue is still enigmatic. Therefore, we aimed to ascertain the impact of GPR37 expression on A2AR traf-
ficking and function in native tissues. To this end, we first assessed A2AR cell surface expression by means of bio-
tynilation of striatal slices, thus enabling the selective quantification of surface expressed receptors in GPR37+/+ 
and GPR37−/− mice. Interestingly, while total A2AR density was unaltered, the A2AR cell surface density was 
increased in the striatum of GPR37−/− mice (Fig. 5A and B). Of note, the absence of tyrosine hydroxylase 
immunoreactivity in the biotinylated surface fractions indicated that the integrity of slices was maintained and no 
major cell damage occurred during striatal slice preparation. Thus, our results demonstrated that GPR37 deletion 
potentiates A2AR cell surface expression.
Figure 1. Co-distribution of GPR37 and A2AR in the mouse brain. (A) Cartoon showing the location of the 
horizontal brain section for the histoblot (left panel). The expected brain regions within the horizontal section 
(right panel) are indicated: Cb, cerebellum; Hp, hippocampus; Ct, cortex; St, striatum (blue); Call, corpus 
callosum. (B) Histoblots from horizontal sections (see panel A) of GPR37+/+ and GPR37−/− mouse brain. 
GPR37 and A2AR were detected using a rabbit anti-GPR37-N antibody (3 μg/ml) and a goat anti-A2AR antibody 
(3 μg/ml) (see Materials and Methods). (C) The histoblots were scanned and densitometric measurements from 
six independent experiments were averaged to compare the GPR37 and A2AR protein densities. Since expression 
was maximal in corpus callosum, normalization was performed assigning it the 100%. Results are expressed as 
mean ± SEM. Scale bar: 0.4 cm.
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Next, we examined whether the increased A2AR cell surface expression in GPR37−/− striatum translated into 
an increased A2AR function. To this end, we evaluated A2AR-dependent cAMP accumulation in striatal nerve 
terminals from GPR37+/+ and GPR37−/− mice. First, we undertook a complementary double immunocyto-
chemistry study in individual striatal synaptosomes to identify synapses endowed with both GPR37 and A2AR 
(Fig. 5C). As illustrated in Fig. 5D, we observed that around 9 ± 1.1% of total population of striatal synapto-
somes (immunopositive for both SNAP25 and PSD95), presented immunoreactivity for both GPR37 and A2AR 
(Fig. 5D). Subsequently, we compared the ability of an A2AR agonist to trigger cAMP accumulation in striatal 
Figure 2. Subsynaptic distribution of GPR37 in the mouse striatum. (A) Electron micrographs showing 
immunoparticles for GPR37 in the striatum of GPR37+/+ mice using the pre-embedding immunogold 
technique. GPR37 immunoparticles were abundant on the extrasynaptic plasma membrane (arrows) of 
dendritic spines (s) of striatal neurons contacted by axon terminals (at). Few immunoparticles were observed at 
intracellular sites (crossed arrows) in dendritic spines (s) (upper panel). Immunoparticles for GPR37 were also 
localized to the extrasynaptic plasma membrane (arrowheads) of axon terminals (at) establishing asymmetrical 
synapses with spines (s). In dendritic shafts (Den), immunoparticles for GPR37 were mainly found at the 
plasma membrane (arrows) (lower panel). Scale bars: 200 nm. (B) Bar graphs showing the percentage of GPR37 
immunoparticles at post- and presynaptic compartments. The data are expressed as mean ± SEM of three 
independent experiments (***P < 0.001; Student’s t-test). (C) Representative immunoblots showing GPR37 
and A2AR immunoreactivity in striatal synaptic fractions. Striatal synaptosomes (Total) were subcellularly 
fractionated (see Materials and Methods section) into extrasynaptic (Extra), presynaptic active zone (Pre) 
and postsynaptic density (Post) fractions, which were analyzed by SDS-PAGE (20 μg of protein/lane) and 
immunoblotted using rabbit anti-GPR37-N, goat anti-A2AR, rabbit anti-synaptophysin, mouse anti-PSD-95, 
mouse anti-SNAP-25 and rabbit anti-α-actinin antibodies. The primary antibodies were detected using a 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG, HRP-conjugated goat anti-mouse IgG, HRP-
conjugated rabbit anti-goat IgG and chemiluminescence detection (see Materials and Methods). (D) Relative 
quantification of GPR37 enrichment in striatal presynaptic and postsynaptic fractions. The intensities of the 
immunoreactive bands on the immunoblotted membranes corresponding to extrasynaptic, presynaptic (Pre) 
and postsynaptic (Post) fractions were measured by densitometric scanning. Values were first normalized to 
the loading control (i.e. α-actinin) and then to the amount of GPR37 or A2AR in the total fraction. Data are 
expressed as mean ± SEM of three independent experiments (*P < 0.05, Student’s t-test).
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synaptosomes from GPR37+/+ and GPR37−/− mice. A significant 2.5-fold increase in A2AR-mediated cAMP 
accumulation was observed in synaptosomes from GPR37−/− mice (Fig. 5E). Finally, similar A2AR-based func-
tional assays were performed in striatal primary neurons from GPR37+/+ and GPR37−/− mice (Fig. 5F). Again, 
a significant increase in A2AR-mediated cAMP accumulation was observed in primary cultures from GPR37−/− 
striatum (Fig. 5G). Overall, these results demonstrated that GPR37 deletion bolstered striatal A2AR cell surface 
expression as well as A2AR function.
GPR37 deletion enhances A2AR function in vivo. Once we confirmed an enhanced striatal A2AR activity 
in GPR37−/− mice, we aimed to determine its impact in animal behavior. It is well established that striatal A2AR 
modulates the central processes involved in locomotor activity and psychomotor behaviors due to its interplay 
with the dopaminergic system27. Our data predicted an enhanced modulation of locomotor activity by striatal 
A2AR in GPR37−/− mice. Since it is well-known that blocking of A2AR increases spontaneous locomotor activity 
in mice28, we compared the hyper-motility induced by an A2AR antagonist in GPR37+/+ and GPR37−/− mice. 
To this end, we challenged GPR37+/+ and GPR37−/− mice with SCH58261 and the spontaneous locomotor 
Figure 3. Post-embedding electron microscopy showing GPR37 and A2AR co-localization in the mouse 
striatum. Electron micrographs from GPR37+/+ and GPR37−/− showing immunoreactivity for GPR37 and 
A2AR in the striatum revealed using a double-labelling post-embedding immunogold technique. (A–D) In 
GPR37+/+ mice, immunoparticles for A2AR (10 nm size) and GPR37 (20 nm size) were closely co-distributed 
(circles) along the extrasynaptic plasma membrane of dendritic shafts (Den) and dendritic spine (s) establishing 
excitatory synaptic contact with axon terminals (b). (E) In GPR37−/− mice, immunoparticles for A2AR (10 nm 
size) are present in the tissue but not immunoparticles for GPR37, demonstrating the full specificity of the anti-
GPR37-N antibody. Scale bars: A–E, 500 nm.
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activity in an open field arena was monitored (Fig. 6A). Our results showed that A2AR antagonist-mediated loco-
motor activity potentiation was significantly (P < 0.05) higher in GPR37−/− mice (Fig. 6B), thus suggesting an 
increased A2AR basal activity in the absence of GPR37.
Conversely to hyperlocomotion induced by A2AR antagonists, activation of striatal A2AR with selective ago-
nists can suppress motor activity, thus producing effects that resemble those yielded by D2R antagonists (i.e. 
haloperidol) or dopamine depletion (i.e. reserpine)29. For instance, administration of the A2AR agonist CGS 21680 
blocked acquisition and expression of wheel running behavior30, depressed locomotor activity31 and induced 
catalepsy32. We now assessed whether A2AR agonist-induced catalepsy was increased in GPR37−/− mice. Our 
results showed that upon CGS21680 administration (i.c.v.) the catalepsy scores of GPR37−/− mice were signif-
icantly higher (P < 0.001) than these observed in GPR37+/+ mice (Fig. 6C), thus demonstrating an increased 
activity of striatal A2AR in GPR37−/− mice. Overall, our results suggested that GPR37 may modulate A2AR 
control of locomotor activity and psychomotor behavior through a putative GPR37/A2AR heteromer. Needless 
to say, as commented previously, GPCR display the ability to oligomerize, but receptors may also exist in their 
monomeric form. Accordingly, the observed effects of A2AR ligands on locomotor activity and psychomotor 
activity would be interpreted within this more complex scenario, in which different populations of receptors exist, 
forming or not heteromers.
Discussion
GPR37 is an orphan GPCR highly expressed throughout the brain. Although it has been related to the dopa-
minergic system15 and brain myelination4, the physiological role of this receptor has not been fully elucidated. 
Figure 4. GPR37 and A2AR interact in the striatum. (A) Representative images of GPR37 and A2AR 
immunoreactivities in the dorsal striatum of GPR37+/+ and GPR37−/− mice. Superimposition of images 
revealed receptor co-distribution in yellow (merge). Scale bar: 350 μm. Cc, corpus callossum; St; striatum. (B) 
Photomicrographs of dual recognition of GPR37 and A2AR with P-LISA in striatal sections from GPR37+/+ 
and GPR37−/− mice. Scale bar: 10 μm. (C) Quantification of P-LISA signals for GPR37 and A2AR proximity 
in GPR37+/+ and GPR37−/−. Values in the graph correspond to the mean ± SEM (dots/nuclei) of at least five 
animals for each condition. Asterisk indicates statistically significant differences (p < 0.05; Student’s t-test) when 
comparing GPR37−/− with GPR37+/+.
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Recently, by using a modified membrane yeast two-hybrid (MYTH) approach, GPR37 was identified as a putative 
A2AR interacting partner18, prompting the exploration of the biological relevance of this interaction in the native 
brain. Our experimental data strongly supports the existence of GPR37/A2AR heteromers in the mouse striatum. 
Thus, the former GPR37-A2AR interaction picked up in vitro by MYTH18 was further validated in native tissue by 
double-labelling immunogold electron microscopy and P-LISA, which permitted to definitely establish the exist-
ence of a close proximity between these two receptors in the mouse striatum. These findings prompted us to assess 
the impact of this oligomer in animal behavior. Accordingly, our main objective consisted of unravelling the in 
vivo consequences of GPR37/A2AR heteromer formation, the fingerprint for any named GPCR oligomer33. Thus, 
while we can’t rule out existence of a heteromer-independent functional interplay, the following findings shed 
light regarding the in vivo function of the newly described striatal GPR37/A2AR heteromer: i) GPR37 and A2AR 
Figure 5. GPR37 deletion bolsters striatal A2AR cell surface expression and function. (A) Coronal brain slices 
(300 µm) from GPR37+/+ and GPR37−/− mice were prepared and biotinylated as described in Material and 
Methods section. Total and cell surface extracts were analyzed by SDS-PAGE and immunoblotting as described 
in Fig. 2. (B) Quantification of A2AR cell surface density in GPR37+/+ and GPR37−/− striatum. Cell surface 
density was normalized using the total density of A2AR and expressed as mean ± SEM from six independent 
experiments. The asterisk indicates statistically significant difference from the control condition (P < 0.05; 
paired Student’s t test). (C) Co-distribution of GPR37 and A2AR in striatal synaptosomes. Immunofluorescence 
detection of GPR37 (red) and A2AR (green) in striatal total synaptosomes was performed as described in 
Materials and Methods. Superimposition of images (merge) reveals co-localization in yellow (arrows). (D) 
Quantification of synaptosomes expressing GPR37 and/or A2AR. The data are expressed as the percentage 
(mean ± SEM) of total number of synaptosomes that are endowed with GPR37 and/or A2AR, quantified in 
3–4 different synaptosomal preparations from different mice, in which four different fields acquired from 
two different coverslips were analysed in each preparation. (E) A2AR-mediated cAMP accumulation in 
synaptosomes. Total striatal synaptosomes from GPR37+/+ and GPR37−/− mice were stimulated with 500 
nM CGS21680 for 30 min at 37 °C and the cAMP accumulation was measured as described in Materials and 
Methods. The data are expressed as percentage (mean ± SEM) of forskolin-induced cAMP accumulation 
from eight independent experiments, which was similar (P > 0.05) in both genotypes. The asterisks indicate 
statistically significant difference from the control condition (P < 0.01; Student’s t test). (F) Co-distribution 
of GPR37 and A2AR in striatal neurons. Immunofluorescence detection of GPR37 (red) and A2AR (green) 
in primary cultured striatal neurons (DIV21) was performed as described in Materials and Methods. 
Superimposition of images (merge) reveals co-localization in yellow. Scale bar: 100 μm. (G) A2AR-mediated 
cAMP accumulation in striatal neurons. Striatal primary neurons from GPR37+/+ and GPR37−/− were 
stimulated with 500 nM CGS21680 for 30 min at 37 °C and the cAMP accumulation was measured as described 
in Materials and Methods. The data are expressed as percentage (mean ± SEM) of forskolin-induced cAMP 
accumulation from five independent experiments, which was similar (P > 0.05) in both genotypes. The asterisks 
indicate statistically significant difference from the control condition (P < 0.01; Student’s t test).
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displayed a high and selective anatomical proximity within striatal spines; ii) GPR37 deletion potentiated A2AR 
cell surface targeting in striatal slices; iii) A2AR-mediated signaling was enhanced in striatal synaptosomes and 
primary cultures from GPR37−/−; iv) GPR37 deletion potentiated A2AR antagonist-mediated locomotor activity 
and A2AR agonist-induced catalepsy. Based on these data, we concluded that GPR37 is a negative modulator of 
A2AR cell surface expression and function in vivo, and whether the formation of the GPR37/A2AR heteromer is 
required for these effects should be further explored in the near future.
The striatum, the main input structure of the basal ganglia34, is responsible for both movement and learn-
ing/reward behavior. Importantly, dopaminergic projections from the substantia nigra pars compacta (SNc) are 
essential for motor control and their degeneration in PD results in severe motor problems35. Indeed, conventional 
therapies for PD are primarily devoted to replacing and support dopaminergic neurotransmission. In such way, 
early PD motor symptoms respond well to dopamine-based therapies including levodopa and D2R agonists36. 
However, in the long term, these agents may lead to the development of serious motor complications that limit 
their efficacy37. These therapeutic obstacles have prompted the search for alternative therapies based on novel 
nondopaminergic drug38. A new therapeutic target is the adenosinergic system. In fact, A2AR antagonists have not 
only been postulated but they have also been licensed as antiparkinsonian drugs39. Importantly, it is believed that 
the A2AR/D2R heterodimer may underlie the observed antiparkinsonian effects of A2AR antagonists40. In addition, 
the striatal A2AR/D2R heterodimer has been shown to be downregulated in experimental parkinsonism19, a fact 
that parallels a concomitant increase in A2AR constitutive activity28.
The ability of striatal GPR37 to oligomerize with A2AR, and possibly with D2R, might constitute a way for 
fine-tuning multiple receptor-signaling pathways and harmonizing dopaminergic neurotransmission. Certainly, 
manipulating the GPR37/A2AR heteromer stoichiometry could impact on D2R functioning through putative post-
synaptic GPR37/D2R/A2AR-containing complexes present in GABAergic striatopallidal neurons. Hence, it could 
be hypothesized that an increased GPR37/A2AR oligomerization would repress A2AR activity and, therefore, indi-
rectly rise D2R function, mimicking the effects of a direct activation of the receptor. This last hypothesis still needs 
to be experimentally probed, but it seems clear that the GPR37/A2AR heteromer, which here we demonstrate is 
formed in native conditions, may constitute a novel and very attractive target for the design of new pharmacolog-
ical strategies to manage pathologies affecting dopaminergic neurotransmission such as PD.
Methods
Animals. C57BL/6J wild type (GPR37+/+) and GPR37 deficient (GPR37−/−) male mice (Strain Name: 
B6.129P2-GPR37tm1Dgen/J; The Jackson Laboratory, Bar Harbor, ME, USA) with 8 weeks of age were used2. The 
University of Barcelona Committee on Animal Use and Care approved the protocol. Animals were housed and 
tested in compliance with the guidelines described in the Guide for the Care and Use of Laboratory Animals41 and 
following the European Union directives (2010/63/EU). All efforts were made to minimize animal suffering and 
Figure 6. GPR37 deletion promotes A2AR-mediated behavior. (A) A2AR antagonist-induced locomotor 
hyperactivity in GPR37+/+ and GPR37−/− mice. Representative 10 min trajectories in an open field arena 
of GPR37+/+ and GPR37−/− mice administered intraperitoneally with vehicle or SCH58261 (3.75 mg/
kg). (B) Quantification of the horizontal locomotor activity shown in (A). The distance travelled is expressed 
as mean ± SEM (n = 10 animals) *P < 0.05, **P < 0.01 SCH58261 treatment effect (one-way ANOVA, 
followed by Tukey post-hoc test), #P < 0.05 phenotype effect (two-way ANOVA, Bonferroni post-hoc test). 
(C) A2AR agonist-induced catalepsy in GPR37+/+ and GPR37−/− mice. The cataleptic response induced by 
intracerebroventricular administration of CGS21680 (10 µl of a 1 µg/µl solution) in GPR37+/+ and GPR37−/− 
mice was measured as the duration of an abnormal upright posture in which the forepaws of the mouse were 
placed on a horizontal wooden bar. The time spent with both front paws resting on the bar is expressed as 
mean ± SEM (n = 10 animals); a cut off time was set at 200 s. **P < 0.01, ***P < 0.001 CGS21680 treatment 
effect (one-way ANOVA, followed by Tukey post-hoc test); #P < 0.05 phenotype effect (Two-way ANOVA, 
Bonferroni post-hoc test).
www.nature.com/scientificreports/
9SCIENTIFIC RePoRTS | 7: 9452  | DOI:10.1038/s41598-017-10147-x
the number of animals used. All animals were housed in groups of five in standard cages with ad-libitum access 
to food and water and maintained under 12 h dark/light cycle (starting at 7:30 AM), 22 °C temperature, and 66% 
humidity (standard conditions).
Immunohistoblotting. The regional distribution of GPR37 and A2AR was analyzed in the C57BL6 mouse 
brain using an in situ blotting technique42, 43. Briefly, horizontal cryostat sections (25 µm) were placed on nitro-
cellulose membranes 0.45 µm (Whatman) moistened with 48 mM Tris-base, 39 mM glycine, 2% (w/v) SDS and 
20% (v/v) methanol for 15 min at room temperature (~20 °C). After blocking in 5% (w/v) non-fat dry milk in 
phosphate-buffered saline, the nitrocellulose membranes were treated with Deoxyribonuclease I from bovine 
pancreas (DNase I, 5 U/mL, Sigma-Aldrich, St. Louis, MO, USA), washed and incubated in 2% (w/v) SDS and 
100 mM β-mercaptoethanol in 100 mM Tris–HCl (pH 7.0) for 60 min at 45 °C to remove adhering tissue resi-
dues. After extensive washing, the blots were incubated overnight at 4 °C with rabbit anti-GPR37-N polyclonal 
antibody (3 µg/ml)2 or goat anti-A2AR polyclonal antibody (AB_2571655; 3 µg/ml; Frontier Institute Co. Ltd, 
Shinko-nishi, Ishikari, Hokkaido, Japan) in blocking solution. The bound primary antibodies were detected with 
alkaline phosphatase-conjugated secondary antibodies. All nitrocellulose membranes were processed in parallel, 
using the same incubation times and antibody/reagent concentrations. Digital images were acquired with a Stereo 
Lumar.v12.
Fixed brain tissue preparation. Mice were anesthetized and perfused intracardially with 100 ml of 
ice-cold 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS; 8.07 mM Na2HPO4, 1.47 mM KH2PO4, 
137 mM NaCl, 0.27 mM KCl, pH 7.2). Brains were post-fixed overnight in the same solution of PFA at 4 °C. 
Coronal sections (50 μm) were obtained using a vibratome (Leica Lasertechnik GmbH, Heidelberg, Germany). 
Slices were collected in Walter’s Antifreezing solution (30% glycerol, 30% ethylene glycol in PBS, pH 7.2) and kept 
at −20 °C until processing.
Immunoelectron microscopy. Pre-embedding immunogold technique. Immunohistochemical reactions 
for electron microscopy were carried out using the pre-embedding immunogold method described previously44. 
Briefly, free-floating sections were incubated in 10% (v/v) NGS (normal goat serum) diluted in TBS. Sections 
were then incubated with rabbit anti-GPR37-N (3–5 μg/ml diluted in TBS containing 1% (v/v) NGS), followed 
by incubation in goat anti-rabbit IgG coupled to 1.4 nm gold (Nanoprobes Inc., Stony Brook, NY, USA). Sections 
were post-fixed in 1% (v/v) glutaraldehyde and washed in double-distilled water, followed by silver enhancement 
of the gold particles with an HQ Silver kit (Nanoprobes Inc.). Sections were then treated with osmium tetraoxide 
(1% in 0.1 m phosphate buffer), block-stained with uranyl acetate, dehydrated in graded series of ethanol and 
flat-embedded on glass slides in Durcupan (Fluka, Sigma-Aldrich) resin. Regions of interest were cut at 70–90 
nm on an ultramicrotome (Reichert Ultracut E, Leica, Austria) and collected on single slot pioloform-coated 
copper grids. Staining was performed on drops of 1% aqueous uranyl acetate followed by Reynolds’s lead citrate. 
Ultrastructural analyses were performed in a Jeol-1010 electron microscope. To study the frequency of GPR37, 
we counted immunoparticles identified in each reference area and present in different subcellular compartments: 
dendritic spines, dendritic shafts and axon terminals. The data were expressed as a percentage of immunoparticles 
in each subcellular compartment, both in the plasma membrane and at intracellular sites.
Post-embedding immunogold technique. To study the spatial relationship between A2AR and GPR37 we used 
double-labelling post-embedding immunogold techniques, as previously described45. Briefly, ultrathin sections 
80-nm thick from Lowicryl-embedded blocks of striatum were picked up on coated nickel grids and incubated 
on drops of a blocking solution consisting of 2% human serum albumin (HSA) in 0.05 M TBS and 0.03% Triton 
X-100 (TBST). The grids were incubated with a mixture of goat anti-A2AR and rabbit anti-GPR37-N (10 μg/ml 
in TBST with 2% HSA)2 at 28 °C overnight. The grids were incubated on drops of rabbit anti-goat IgG or goat 
anti-rabbit IgG conjugated to 10 nm and 20 nm colloidal gold particles, respectively (BBI Solutions, Cardiff, 
UK) in 2% HSA and 0.5% polyethylene glycol in TBST. The grids were then washed in TBS and counterstained 
for electron microscopy with saturated aqueous uranyl acetate followed by lead citrate. Ultrastructural analyses 
were performed in a Jeol-1010 electron microscope. Randomly selected areas were then photographed from the 
selected ultrathin sections at a final magnification of 50,000 x.
Gel electrophoresis and immunoblotting. Sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (SDS/PAGE) was performed using 10% polyacrylamide gels. Proteins were transferred to polyvinylidene 
difluoride membranes using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA) and immunoblot-
ted using rabbit anti-GPR37-N (1 μg/ml)2, goat anti-A2AR (AB_2571655; 1 μg/ml; Frontier Institute Co. 
Ltd), rabbit anti-synaptophysin (ab23754; 1 μg/ml; Abcam), mouse anti-PSD-95 (ab13552; 1 μg/ml; Abcam), 
mouse anti-SNAP-25 (ab66066; 1 μg/ml; Abcam) and rabbit anti-α-actinin (sc-15335; 0.5 μg/ml; Santa Cruz 
Biotechnology Inc., Dallas, TX, USA) antibodies. The primary antibodies were detected using a horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG (65–6120; 1/50,000; Pierce Biotechnology), HRP-conjugated 
goat anti-mouse IgG (31430; 1/20,000; Pierce Biotechnology), HRP-conjugated rabbit anti-goat IgG (61–1620; 
1/20,000; Pierce Biotechnology). The immunoreactive bands were developed using a chemiluminescent detection 
kit (Thermo Fisher Scientific, Waltham, MA, USA) and detected with an Amersham Imager 600 (GE Healthcare 
Europe GmbH, Barcelona, Spain)46.
Striatal slice biotinylation. Biotinylation is a useful tool for the covalent labelling and separation of 
cell-surface-expressed proteins in brain slices47. In brief, mouse brain was rapidly removed and immediately 
chilled in sucrose-supplemented artificial CSF (SACSF; 2.5 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 
mM CaCl2, 26 mM NaHCO3, 11 mM glucose, and 250 mM sucrose) saturated with 95%O2/5%CO2. Brains were 
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mounted on a Leica vibratome 1200S sectioning system (Leica) and 300 µm coronal sections were made. Sections 
containing the striatum were recovered in ACSF (125 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 
2.4 mM CaCl2, 26 mM NaHCO3, and 11 mM glucose) at 31 °C, during 90 min with 95% O2/5% CO2, then were 
immediately used. Surface proteins were covalently labeled with 0.5 mg/ml sulfo-NHS-SS-biotin in ice-cold 
ACSF for 45 min at 4 °C, with continuous 95%O2/5%CO2 bubbling. Following biotinylation, slices were washed 3 
times in ice-cold ACSF and three times in ice-cold ACSF supplemented with 100 mM glycine. Residual reactive 
biotin was quenched by incubating twice in ice-cold ACSF supplemented with glycine during 25 min at 4 °C with 
continuous 95%O2/5%CO2 bubbling. Subsequently, slices were washed four times with ice-cold ACSF, triturated 
with iced-cold radio-immuno assay (RIPA) buffer (150 mM NaCl, 1% NP-40, 50 mM Tris, 0.5% sodium deoxy-
cholate, and 0.1% SDS, pH 8.0) using a Pasteur pipette and rotated in an end over end rotator during 30 min at 
4 °C. Cellular debris were cleared by centrifugation at 18,000 × g for 15 min at 4 °C and the protein concentration 
was determined using the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology, Rockford, IL, USA). 
Next, 25 µl streptavidin agarose were added to 50 µg striatal lysate in 1 ml RIPA buffer and incubated overnight 
with constant rotation at 4 °C. Finally, streptavidin beads were washed five times with RIPA buffer and resus-
pended SDS-PAGE sample buffer for immunoblot assay. A rabbit anti-tyrosine hydroxylase antibody (AB152; 
Merck Millipore, Darmstadt, Germany) was used to ensure proper cell-surface-protein isolation.
Synaptosomal preparation and subsynaptic fractionation. For synaptosomal preparation the stria-
tum from 6 mice were dissected and homogenized in 1 ml of isolation buffer (0.32 M sucrose, 0.1 mM CaCl2 and 
0.1 mM MgCl2, pH 7.4) at 4 °C in a 5 ml Potter-Elvehjem glass tube using a homogenizer stirrer HS-30E (Witeg 
Labortechnik GmbH, Wertheim, Germany) with 10 strokes at 700–900 rotations per min. The resulting homoge-
nate was mixed with 6 ml sucrose 2 M and 2.5 mL CaCl2 0.1 mM in an ultra-clear centrifuge tube (Beckman 
Coulter, Hospitalet de Llobregat, Spain). Then, 2.5 mL of sucrose 1 M containing 0.1 mM CaCl2 were slowly 
added on top of the tube to form a sucrose gradient. After centrifugation for 3 h at 100,000 x g at 4 °C, the synap-
tosomes were collected as the interphase between 1.25 M and 1 M sucrose. They were diluted 10 times in isolation 
buffer, centrifuged for 30 min at 15,000 × g at 4 °C and the resulting synaptosomal pellet was resuspended in 1 ml 
of isolation buffer for immediate use.
The separation of the presynaptic active zone, postsynaptic density and extrasynaptic fractions from striatal 
synapses was carried out as previously described48. Briefly, synaptosomes were diluted 1:10 in cold 0.1 mM CaCl2 
and an equal volume of 2 x solubilization buffer (2% Triton X-100, 40 mM Tris, pH 6.0) was added to the suspen-
sion. The suspension was incubated for 30 min on ice with constant agitation and the insoluble material (synaptic 
junctions) pelleted (40,000 × g for 30 min at 4 °C). The supernatant (extrasynaptic fraction) was concentrated 
using an Amicon Ultra 15 10K (Merck Millipore) and proteins precipitated with six volumes acetone at −20 °C 
and recovered by centrifugation (18,000 × g for 30 min at −15 °C). The synaptic junctions pellet was washed in 
solubilization buffer (pH 6.0) and resuspended in 10 volumes of a second solubilization buffer (1% Triton X-100, 
20 mM Tris at pH 8.0). After incubation for 30 min on ice with agitation, the mixture was centrifuged and the 
supernatant (presynaptic fraction) processed as described for the extrasynaptic fraction, whereas the insoluble 
pellet corresponds to the postsynaptic fraction. Protease inhibitors (Protease Inhibitor Cocktail Set III, Millipore, 
Temecula, CA, USA) were added to the suspension in all extraction steps. The protein concentration was deter-
mined by the BCA protein assay (Pierce Biotechnology) and 20 ug of each fraction, solubilized in 5% SDS, were 
added to SDS-PAGE sample buffer prior to freezing at −20 °C.
cAMP assay in synaptosomes. Synaptosomal cAMP accumulation was measured using the LANCE 
Ultra cAMP kit (PerkinElmer, Waltham, MA, USA) as previously described49. In brief, total striatal synaptosomal 
membranes (0.5 μg) from GPR37+/+ and GPR37−/− mice were resuspended in stimulation buffer (HBSS 1X, 5 
mM Hepes pH 7.4, 10 mM MgCl2, 0.1% BSA) and subsequently processed for cAMP accumulation. Thus, vehicle, 
forskolin (1 μM; Sigma-Aldrich) or CGS21680 (500 nM; Tocris Biosciences, Bristol, UK) were added for 30 min 
at 22 °C before the lysis and cAMP quantification in a POLARStar microplate reader (BMG Labtech, Durham, 
NC, USA). cAMP levels were calculated as previously described49.
Striatal primary cell culture. Primary striatal neurons were cultured from GPR37+/+ and GPR37−/− 
mice embryos (E18). Briefly, after dissection, the striatum was treated with 1.25% trypsin for 10 min 
(Sigma-Aldrich) and mechanically dissociated with a flame polished Pasteur pipette. Neurons were plated onto 
poly-D-lysine (0.1 mg/ml) and laminin-coated (0.01 mg/ml) 6-wells plate (for cAMP accumulation assay) or 
12-wells plate containing glass coverslips (for immunocytochemistry) in minimum essential medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% horse serum, 10% bovine serum, 1 mM pyruvic acid, and 0.59% glu-
cose at a density of 80,000 cells/cm2. After 4–14 h, the medium was substituted with Neurobasal medium supple-
mented with penicillin (100 U/ml), streptomycin (100 μg/ml), 0.59% glucose, and B27 supplement (Invitrogen). 
Neurons were kept at 5% CO2, 37 °C and 95% humidity for 21 days in vitro (DIV) before the experiments.
Immunofluorescence. For immunohistochemistry of brain slices, these were washed three times with PBS, 
permeabilized with 0.5% Triton X-100 in PBS for 2 hours and rinsed again three times with washing solution 
(0.05% Triton X-100 in PBS). The slices were then incubated with washing solution containing 10% normal don-
key serum (NDS; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 2 h at room tempera-
ture. Subsequently, slices were incubated with a new homemade rabbit anti-GPR37 polyclonal antibody, raised 
using a glutathione S-transferase (GST)-fusion protein containing amino acids 541–600 of GPR37 C terminus 
(anti-GPR37-C: 3 μg/ml), plus goat anti-A2AR (3 µg/ml; Frontier Institute Co. Ltd) in washing solution containing 
10% NDS for 48h at 4 °C. Next, slices were washed with washing solution containing 1% NDS before the incuba-
tion with Cy3-conjugated donkey anti-rabbit IgG antibody (1/200; Jackson ImmunoResearch Laboratories) and 
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Cy2-conjugated donkey anti-goat IgG antibody (1/200; Jackson ImmunoResearch Laboratories) in washing solu-
tion for 2 h at room temperature. Finally, slices were washed twice with 1% NDS in washing solution containing 
10% NDS and then mounted with Vectashield immunofluorescence medium (Vector Laboratories, Peterborough, 
UK) in glass slides. Fluorescence striatal images were captured using a Leica TCS 4D confocal scanning laser 
microscope (Leica Lasertechnik GmbH).
For immunocytochemistry of DIV21 primary striatal neurons, these were grown on poly-D-lysine (0.1 mg/
ml) and laminin-coated (0.01 mg/ml) coverslips, fixed in 4% paraformaldehyde for 15 min and washed with PBS 
containing 20 mM glycine (buffer A) to quench aldehyde groups. Neurons were then permeabilized with buffer 
A containing 0.2% Triton X-100 for 10 min. Subsequently, neurons were labeled for 1 h at 22 °C with a rabbit 
anti-GPR37-N antibody (1 μg/ml) and a goat anti-A2AR (1 μg/ml) washed, and stained with Cy5-conjugated 
donkey anti-rabbit IgG antibody (1/200) and Cy2-conjugated donkey anti-goat IgG antibody (1/200) (Jackson 
ImmunoReserach Laboratories Inc.). Coverslips were rinsed for 3 min in PBS, mounted with Vectashield immu-
nofluorescence medium (Vector Laboratories) and examined using a Leica TCS 4D confocal scanning laser 
microscope (Leica Lasertechnik GmbH, Heidelberg, Germany).
For immunostaining of synaptosomes, total synaptosomes from striatum were fixed in 4% paraformalde-
hyde for 15 min using an end over end tube rotator at room temperature. Subsequently, 100 µl of a 0.125 mg/ml 
synaptosomal suspension was platted onto poly-D-lysine (0.1 mg/ml)-coated coverslips for 1 hour at 37 °C in a 
humidity chamber. Next, coverslips were processed as described for immunocytochemistry experiments with 
cultured neurons. Each coverslip was analysed by counting three different fields.
Proximity ligation in situ assay. Duolink in situ PLA detection Kit (Olink Bioscience, Uppsala, Sweden) 
was performed in a similar manner as immunohistochemistry using rabbit anti-GPR37-C (3 μg/ml) plus goat 
anti-A2AR (3 µg/m) as a primary antibodies and the secondary antibodies following the manufacturer’s protocol, 
as previously described19, 26. Fluorescence images were acquired on a Leica TCS 4D confocal scanning laser micro-
scope (Leica Lasertechnik GmbH) using a 60x N.A. = 1.42 oil objective from the selected area. High-resolution 
images were acquired as a z-stack with a 0.2 μm z-interval with a total thick of 5 μm. Nonspecific nuclear signal 
was eliminated from PLA images by substracting TO-PRO-3 Iodide (Thermo Fisher Scientific) labeling. Analyze 
particle function from Image J (NIH) was used to count particles larger than 0.3 μm2 for PLA signal and larger 
than 100 μm2 to discriminate neuronal from glia nuclei50. For each image several oligomer particles and neuron 
nuclei was obtained and ratio among them was calculated.
Striatal primary cell culture cAMP assay. For cAMP assay, mouse striatal neurons were grown on a 
6-wells plate. On DIV21, cAMP accumulation was measured using the cAMP HiRange assay Kit (CisBio, 
Bagnols-sur-Cèze, France). The growing media of striatal neurons was replaced by non-supplemented Neurobasal 
with adenosine deaminase (ADA, 5 µg/well; from Roche Diagnostics GmbH, Mannheim, Germany) and incu-
bated for 2h. Subsequently, zardaverine (50 μM; Tocris Bioscience) was added and incubated for 30 min at 37 °C. 
Next, vehicle, forskolin (1 μM; Sigma-Aldrich) or CGS21680 (500 nM; Tocris Biosciences) were added for 30 min 
at 37 °C before the lysis with 250 µl of lysis buffer (CisBio). The neuronal extract was centrifuged at 13,000 × g for 
30 min at 4 °C. The cAMP content in 10 µl of the supernatant was determined as previously described49.
Catalepsy induction test. Catalepsy was induced in mice by the intracerebroventricular (i.c.v.) adminis-
tration of CGS21680 (10 µg), as previously described51. The cataleptic response was measured as the duration of 
an abnormal upright posture in which the forepaws of the mouse were placed on a horizontal wooden bar (0.6 
cm of diameter) that was located 4.5 cm above the floor. The latency to move at least one of the two forepaws was 
recorded 2h after CGS21680 administration.
Open-field test. To evaluate the spontaneous locomotor activity, we performed the open field test. In brief, 
the mice were placed in the center of an activity field arena (30 × 30 cm, surrounded by four 50 cm high black 
painted walls) equipped with a camera above to record activity. Mice were administered (ip) with vehicle or 
SCH58261 (3.75 mg/kg; Abcam Biochemicals, Cambridge, UK) 15 min before measuring the exploratory behav-
ior of the animals during a 10-min period. The total distance travelled and the activity within the outer and inner 
zone of the open field was analyzed using Spot tracker function from Image J (NIH). All behavioral tests were 
carried out in a sound attenuated room with 15 lux illumination. The apparatus and the objects were cleaned with 
a 70% alcohol solution and rinsed with water after each session.
Statistics. The number of samples (n) in each set of experimental conditions is indicated in figure legends. 
Statistical analysis was performed by one-way ANOVA followed by Tukey post-hoc test, two-way ANOVA fol-
lowed by Bonferroni post-hoc test or Student’s t-test when appropriate. Statistical significance was considered at 
P < 0.05.
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